NEW YORK (GenomeWeb) – Angsana Molecular & Diagnostics has announced a partnership with Ignyta on screening for a cancer therapy clinical trial being conducted in Asia.
Under the terms of the agreement, Angsana will provide cancer screening using its RNA-based cancer panel to detect TRK, ROS1, and ALK fusions in patients participating in the STARTRK-2 Phase 2 basket trial for entrectinib, a tyrosine kinase inhibitor. The firm will support the trial from its CAP-accredited labs in Singapore and Hong Kong.
Get the full story This story is free
for registered users
Registering provides access to this and other free content.
Already have an account?